Gelteq Limited (GELS)
NASDAQ: GELS · Real-Time Price · USD
0.4304
-0.0156 (-3.50%)
At close: Oct 19, 2026, 4:00 PM EDT
0.4301
-0.0003 (-0.07%)
After-hours: Oct 19, 2026, 4:22 PM EDT
Gelteq Revenue
Gelteq had revenue of 89.30K AUD in the quarter ending December 31, 2025, with 48.92% growth. This brings the company's total for the last twelve months to 471.80K, up 153.17% year-over-year. In the fiscal year ending June 30, 2025, Gelteq had annual revenue of 413.13K with 188.27% growth. That makes Gelteq the 45,036th largest company in the world by revenue and 6,488th in the United States.
Revenue (ttm)
471.80K AUD
Revenue Growth
+153.17%
P/S Ratio
15.85
Revenue / Employee
58,975 AUD
Employees
8
Market Cap
4.81M USD
Revenue by Geography
- United States of America 125.65K 75.9%
- Australia 40.00K 24.1%
Fiscal year ended Jun 30, 2025 See the full Gelteq breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 413.13K | 269.82K | 188.27% |
| Jun 30, 2024 | 143.31K | -199.59K | -58.21% |
| Jun 30, 2023 | 342.90K | -29.17K | -7.84% |
| Jun 30, 2022 | 372.07K | 212.20K | 132.73% |
| Jun 30, 2021 | 159.87K | - | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Biofrontera | 46.18M |
| IM Cannabis | 32.25M |
| Sonoma Pharmaceuticals | 21.92M |
| cbdMD | 20.93M |
| Universe Pharmaceuticals INC | 17.74M |
| InMed Pharmaceuticals | 4.94M |
| RedHill Biopharma | 286.00K |
| Optimi Health | 123.70K |
GELS News
- 4 months ago - Gelteq Transcript: Planet MicroCap Las Vegas 2026 - Transcripts
- 4 months ago - Gelteq Provides Corporate Update: Launching Veterinary and Human Clinical Trials, Pharmaceutical Pipeline Expanding Across Multiple Programs - GlobeNewsWire
- 4 months ago - Gelteq Successfully Completes Veterinary Palatability Trials with Kemin, Further Validating Gelteq® Technology for Animal Health Applications - GlobeNewsWire
- 4 months ago - Gelteq Establishes Center of Excellence in China to Accelerate Product Development and Commercial Expansion - GlobeNewsWire
- 5 months ago - Gelteq Commences Veterinary Medicine Clinical Trial to Support an FDA Regulatory Pathway - GlobeNewsWire
- 5 months ago - Healthy Extracts Q1 2026 Net Revenue Up 73% to Record $1.6 Million, Driving Positive EBITDA - Accesswire
- 5 months ago - Gelteq Announces USD $3.5 Million Strategic Debt Financing to Accelerate Commercialization and Support Revenue Growth - GlobeNewsWire
- 6 months ago - Healthy Extracts Reports 2025 Net Revenue Up 45% to Record $4.5 Million - Accesswire